logo-loader
EnergyOil & Gas
Hawkley Oil & Gas

Hawkley Oil and Gas flows gas from secondary target at Ukraine well

au_ukraine_map350_506ba19ba69e1.jpg

Hawkley Oil & Gas (ASX: HOG) has flowed gas from a secondary target interval at its Sorochynska-202 development well in Ukraine, confirming the existence of a substantial gas resource.

While the unstimulated test of the Lower B19 horizon did not result in commercial flows, which could be due to a reservoir quality issue or possibly formation damage, it did confirm the horizon is gas saturated, in line with expectations and supporting the work completed by independent engineers Moyes & Co.

The core sample from the well is being analysed and will be integrated with well test data to determine the appropriate technology and potentially well stimulation techniques to exploit the Lower B19.

Notably, a much higher flow rate was reported from a drill stem test of the Lower B19 in Sorochynska 469 in 1982.

Hawkley will now carry out production testing of the Upper B19 as well as Upper and Lower B18 sands.

Sorochynska 202 was drilled to provide an additional offtake point for the main Upper B18 sand.

While reservoir development of the Upper B18 appears to be slightly less than prognosed at this location, it is mitigated by the improved development of the Lower B18 with the total pay in both B18 sands being close to expectation.

Sorochynska 202 could double Hawkley’s production from the Sorochynska field.

 

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

Quick facts: Hawkley Oil & Gas

Price: $0.00

Market: ASX
Market Cap: $994.23 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

8 hours, 53 minutes ago

2 min read